PMCB Key Statistics, Chart & Performance
The current stock price of PMCB is 0.9283 USD. In the past month the price increased by 33.63%. In the past year, price decreased by -40.87%.
PMCB Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to PMCB. When comparing the yearly performance of all stocks, PMCB is a bad performer in the overall market: 85.38% of all stocks are doing better.
PMCB Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PMCB. PMCB has a great financial health rating, but its profitability evaluates not so good.
PMCB Financial Highlights
Over the last trailing twelve months PMCB reported a non-GAAP Earnings per Share(EPS) of -1.32. The EPS decreased by -248.76% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -16.03% | ||
| ROE | -24.55% | ||
| Debt/Equity | 0 |
PMCB Forecast & Estimates
PMCB Ownership
PMCB Latest News, Press Relases and Analysis
About PMCB
Company Profile
PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. The company is headquartered in Las Vegas, Nevada and currently employs 2 full-time employees. The company went IPO on 2003-09-11. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.
Company Info
PHARMACYTE BIOTECH INC
3960 Howard Hughes Parkway, Suite 500
Las Vegas NEVADA US
CEO: Kenneth L. Waggoner
Employees: 2
Phone: 19175952850
PHARMACYTE BIOTECH INC / PMCB FAQ
What does PMCB do?
PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. The company is headquartered in Las Vegas, Nevada and currently employs 2 full-time employees. The company went IPO on 2003-09-11. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.
Can you provide the latest stock price for PHARMACYTE BIOTECH INC?
The current stock price of PMCB is 0.9283 USD. The price decreased by -2.28% in the last trading session.
Does PMCB stock pay dividends?
PMCB does not pay a dividend.
How is the ChartMill rating for PHARMACYTE BIOTECH INC?
PMCB has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists PMCB stock?
PMCB stock is listed on the Nasdaq exchange.
Can you provide the market cap for PHARMACYTE BIOTECH INC?
PHARMACYTE BIOTECH INC (PMCB) has a market capitalization of 6.31M USD. This makes PMCB a Nano Cap stock.